Blood testing now a $100 million business for Chiron:
This article was originally published in Clinica
Executive Summary
Blood testing business revenues at Chiron rose 14% last year, to $113 million. The Emeryville, California-based company's last piece of diagnostics business, retained after the sale of the remainder to Bayer Diagnostics, rose principally because of sales of $7 million recorded in nucleic acid testing (NAT) and Chiron's joint venture with Johnson & Johnson's Ortho-Clinical Diagnsotics in immunoassay blood testing.